Astellas Pharma Inc. (TYO: 4503)
Japan
· Delayed Price · Currency is JPY | Market Cap | 2.81T |
| Revenue (ttm) | 1.77T |
| Net Income (ttm) | 54.75B |
| Shares Out | 1.79B |
| EPS (ttm) | 30.44 |
| PE Ratio | 51.66 |
| Forward PE | 26.20 |
| Dividend | 74.00 (4.74%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 3,567,200 |
| Open | 1,585.00 |
| Previous Close | 1,572.50 |
| Day's Range | 1,573.50 - 1,598.50 |
| 52-Week Range | 1,426.00 - 1,839.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2024 |
About Astellas Pharma
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAG... [Read more]
Financial Performance
In 2023, Astellas Pharma's revenue was 1.60 trillion, an increase of 5.60% compared to the previous year's 1.52 trillion. Earnings were 17.05 billion, a decrease of -82.73%.
Financial StatementsNews
Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management
SAN FRANCISCO , Nov. 20, 2024 /PRNewswire/ -- Astellas Pharma U.S., Inc. (President: Mike Petroutsas, "Astellas") today announced that it has entered into an agreement with Desert Oasis Healthcare (DO...
Astellas Pharma Inc. (ALPMF) Q2 2024 Earnings Call Transcript
Astellas Pharma Inc. (OTCPK:ALPMF) Q2 2024 Earnings Call Transcript October 30, 2024 2:30 AM ETCompany ParticipantsHiromitsu Ikeda - Chief Communications...
Astellas: Can The Gastric Cancer Approval Be The Inflection Point?
Astellas: Can The Gastric Cancer Approval Be The Inflection Point?
Astellas Pharma reports H1 results
Astellas wins FDA nod for first-line gastric cancer therapy
Astellas Pharma's antibody drug Vyloy approved by the FDA with chemotherapy for first-line treatment of gastric or GEJ adenocarcinoma in certain adults. Read more here.
Astellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer
VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO , Oct. 18, 2...
FDA approves Astellas' gastric cancer therapy
The U.S. Food and Drug Administration approved Astellas' gastric cancer therapy, the health regulator's website showed on Friday.
Astellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on Menopause
TOKYO , Oct. 10, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") announced that VEOZA™ (fezolinetant)*, its first-in-class treatment for moderate t...
Astellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on Menopause
TOKYO , Oct. 10, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced that VEOZA™ (fezolinetant)*, its first-in-class treatment for moderate to...
Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications
Astellas receives an exclusive option to license AVB-101, an investigational, AAV-based gene therapy in Phase 1/2 development AviadoBio receives $20 million equity investment, up to $30 million in up...
eyma Bahi appointed as head of Astellas Pharma Turkey, Middle East and Africa area
In her new role, she will oversee operations across 12 markets
Singlera Genomics and Astellas Present Methylation-based Organ Toxicity Detection at 2024 JSOT Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--Singlera Genomics and Astellas Pharma presented results during the JSOT 2024 Annual Meeting demonstrating that drug-induced testicular toxicity can be detected using cell-f...
Astellas Receives Approval from the European Commission for VYLOY™ (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer
- Zolbetuximab is currently the first and only therapy approved in the European Union to target claudin 18.2, a biomarker positively expressed by 38% of patients with advanced gastric cancer1,2 - Trea...
Astellas Announces FDA Listing of DIGITIVA™ for the Management of Heart Failure
- New digital health solution for heart failure management puts patients at the center of their care by providing ability for at-home disease monitoring - TOKYO , Sept. 18, 2024 /PRNewswire/ -- Astell...
Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024
- Eight abstracts, including two oral presentations, feature new clinical data from Astellas' oncology portfolio and two lead pipeline programs across a broad range of cancer types - TOKYO , Sept. 11,...
Astellas Unveils New Life Sciences Center in Cambridge, Massachusetts to Accelerate the Discovery of Breakthrough Therapies
The Astellas Life Sciences Center hosts the company's first U.S.-based open innovation SakuLab™ incubator space dedicated to fostering pioneering science through collaboration with external partners T...
Astellas to Present VEOZAH™ (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society
- Pooled analyses from two SKYLIGHT™ studies highlight impact on sleep disturbance and impairment, relationship between improvements in the frequency or severity of hot flashes and mood - Pooled data ...
Astellas to Present VEOZAH™ (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society
- Pooled analyses from two SKYLIGHT™ studies highlight impact on sleep disturbance and impairment, relationship between improvements in the frequency or severity of hot flashes and mood - Pooled data ...
European Commission Approves Astellas' PADCEV™ (enfortumab vedotin) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer
- First regimen approved in advanced urothelial cancer to demonstrate superiority to platinum-containing chemotherapy, the standard of care for nearly 40 years1 - European Marketing Authorization base...
Astellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy
- HIGHLIGHT 1™ study to evaluate fezolinetant for treatment of moderate to severe vasomotor symptoms in women with stage 0-3 hormone receptor positive breast cancer receiving adjuvant endocrine therap...
China confirms charges laid against Japanese citizen accused of spying
Accused not identified but Astellas Pharma says one of its Japanese employees has been indicted by Chinese authorities.
Japan's Astellas says employee indicted by China's prosecutors
Chinese authorities have indicted a Japanese employee of Astellas Pharma Inc , who had been detained in China since March 2023 on suspicion of espionage, the Japanese pharmaceutical company said on We...
UK regulator approves Astellas' gastric cancer drug
Britain's health regulator said on Wednesday it has approved Astellas Pharma's drug to treat a type of gastric cancer.
Astellas Pharma Inc. (ALPMF) Q1 2024 Earnings Call Transcript
Astellas Pharma Inc. (OTCPK:ALPMF) Q1 2024 Earnings Conference Call August 1, 2024 3:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and IRO Tadaaki Taniguchi - CMO Claus Zieler -...
Astellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer
- If approved by the European Commission, zolbetuximab would become the first and only CLDN18.2-targeted therapy approved in the European Union - A decision on the EU marketing authorizat...